Lisa H. Lam

3.1k total citations
9 papers, 260 citations indexed

About

Lisa H. Lam is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Lisa H. Lam has authored 9 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 1 paper in Molecular Biology. Recurrent topics in Lisa H. Lam's work include HER2/EGFR in Cancer Research (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Advanced Breast Cancer Therapies (2 papers). Lisa H. Lam is often cited by papers focused on HER2/EGFR in Cancer Research (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Advanced Breast Cancer Therapies (2 papers). Lisa H. Lam collaborates with scholars based in United States, Spain and Switzerland. Lisa H. Lam's co-authors include Rolf A. Stahel, Lukas Bubendorf, Dariusz M. Kowalski, Javier de Castro, Marcello Tiseo, Pilar Garrido, Michael W. Lu, Christina S. Baik, Augusto Villegas and Sanne de Haas and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Lisa H. Lam

9 papers receiving 256 citations

Peers

Lisa H. Lam

ONCOL

PRM

RNMI

G. Groth Germany

M. Blake-Cerda Mexico

Philippe Ronga Germany

Dina Sakaeva Russia

Loretta D’Onofrio Italy

Pamela Trillo Aliaga Italy

Elena Simón Polo Spain

Antonino Scimone Italy

Ignacio Tusquets Spain

Rebecca Shatsky United States

G. Groth Germany

Lisa H. Lam

264 ×1.4

ONCOL

279 ×1.8

PRM

73 ×1.1

RNMI

102 ×1.8

50 ×1.5

Citations per year, relative to Lisa H. Lam Lisa H. Lam (= 1×) peers G. Groth

Countries citing papers authored by Lisa H. Lam

Since Specialization

Citations

This map shows the geographic impact of Lisa H. Lam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa H. Lam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa H. Lam more than expected).

Fields of papers citing papers by Lisa H. Lam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa H. Lam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa H. Lam. The network helps show where Lisa H. Lam may publish in the future.

Co-authorship network of co-authors of Lisa H. Lam

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa H. Lam. A scholar is included among the top collaborators of Lisa H. Lam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa H. Lam. Lisa H. Lam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Schmid, Peter, Peter Savas, Enrique Espinosa, et al.. (2021). Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). Cancer Research. 81(4_Supplement). PS12–28. 9 indexed citations

Ji, Dongmei, Jian Zhang, Junning Cao, et al.. (2020). A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy. Medicine. 99(44). e22886–e22886. 3 indexed citations

Peters, Solange, Rolf A. Stahel, Lukas Bubendorf, et al.. (2018). Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clinical Cancer Research. 25(1). 64–72. 173 indexed citations

Giri, Nagdeep, Lisa H. Lam, Robert R. LaBadie, et al.. (2017). Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers. Cancer Chemotherapy and Pharmacology. 80(6). 1249–1260. 12 indexed citations

Stahel, Rolf A., Lukas Bubendorf, Philip Bonomi, et al.. (2017). Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).. Journal of Clinical Oncology. 35(15_suppl). 8509–8509. 25 indexed citations

Lam, Lisa H., Edmund V. Capparelli, & Razelle Kurzrock. (2016). Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. Cancer Chemotherapy and Pharmacology. 78(2). 427–432. 20 indexed citations

Lam, Lisa H. & Jeremy Sugarman. (2016). Adrenal Suppression With Chronic Topical Corticosteroid Use in Psoriasis Patients.. PubMed. 15(8). 945–8. 8 indexed citations

Lam, Lisa H., et al.. (2015). A Case-Based Approach to Integrating Opioid Pharmacokinetic and Pharmacodynamic Concepts in Cancer Pain Management. The Journal of Clinical Pharmacology. 56(7). 785–793. 3 indexed citations

Lam, Lisa H., et al.. (1996). Feature correlation method for enhancing fermentation development: A comparison of quadratic regression with artificial neural networks. Computers & Chemical Engineering. 20. S407–S412. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact